Publication

Trends in direct oral anticoagulant (DOAC) use: Health benefits and patient preference

de Jong, L. A., Koops, M., Gout-Zwart, J. J., Beinema, M. J., Hemels, M. E. W., Postma, M. J. & Brouwers, J. R. B. J., 1-Dec-2018, In : Netherlands Journal of Medicine. 76, 10, p. 426-430 5 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

de Jong, L. A., Koops, M., Gout-Zwart, J. J., Beinema, M. J., Hemels, M. E. W., Postma, M. J., & Brouwers, J. R. B. J. (2018). Trends in direct oral anticoagulant (DOAC) use: Health benefits and patient preference. Netherlands Journal of Medicine, 76(10), 426-430.

Author

de Jong, L.A. ; Koops, M. ; Gout-Zwart, J.J. ; Beinema, M.J. ; Hemels, M.E.W. ; Postma, M.J. ; Brouwers, J.R.B.J. / Trends in direct oral anticoagulant (DOAC) use : Health benefits and patient preference. In: Netherlands Journal of Medicine. 2018 ; Vol. 76, No. 10. pp. 426-430.

Harvard

de Jong, LA, Koops, M, Gout-Zwart, JJ, Beinema, MJ, Hemels, MEW, Postma, MJ & Brouwers, JRBJ 2018, 'Trends in direct oral anticoagulant (DOAC) use: Health benefits and patient preference', Netherlands Journal of Medicine, vol. 76, no. 10, pp. 426-430.

Standard

Trends in direct oral anticoagulant (DOAC) use : Health benefits and patient preference. / de Jong, L.A.; Koops, M.; Gout-Zwart, J.J.; Beinema, M.J.; Hemels, M.E.W.; Postma, M.J.; Brouwers, J.R.B.J.

In: Netherlands Journal of Medicine, Vol. 76, No. 10, 01.12.2018, p. 426-430.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

de Jong LA, Koops M, Gout-Zwart JJ, Beinema MJ, Hemels MEW, Postma MJ et al. Trends in direct oral anticoagulant (DOAC) use: Health benefits and patient preference. Netherlands Journal of Medicine. 2018 Dec 1;76(10):426-430.


BibTeX

@article{900b46a841f2470ca3509d56a1331f2e,
title = "Trends in direct oral anticoagulant (DOAC) use: Health benefits and patient preference",
abstract = "In 2012, the Dutch Health Council published a report addressing barriers for an early and broad introduction of direct oral anticoagulants (DOACs). The report raised concerns about the lack of an antidote, adherence, lack of monitoring in the case of overdose and the increased budget impact at DOAC introduction. In the past decade, international studies have shown that DOACs can provide healthcare benefits for a large number of patients. This has led to an increase in the prescription of DOACs, as they are an effective and user-friendly alternative to vitamin K antagonists (VKAs). Unlike VKAs, DOACs do not need monitoring of the international normalized ratio due to more predictable pharmacokinetics. However, the number of prescriptions of DOACs in the Netherlands is still lagging, compared to other European countries. This article highlights the potential health gains in the Netherlands if the use of DOACs were to increase, based on current international experience.",
keywords = "Coumarins, DOAC, Health benefits, NOAC, Patient preferences, VKA, adult, budget, controlled study, drug overdose, drug therapy, human, international normalized ratio, monitoring, Netherlands, patient preference, pharmacokinetics, prescription, review, antidote, antivitamin K, coumarin derivative",
author = "{de Jong}, L.A. and M. Koops and J.J. Gout-Zwart and M.J. Beinema and M.E.W. Hemels and M.J. Postma and J.R.B.J. Brouwers",
year = "2018",
month = "12",
day = "1",
language = "English",
volume = "76",
pages = "426--430",
journal = "The Netherlands Journal of Medicine",
issn = "0300-2977",
publisher = "van Zuiden Communications BV.",
number = "10",

}

RIS

TY - JOUR

T1 - Trends in direct oral anticoagulant (DOAC) use

T2 - Health benefits and patient preference

AU - de Jong, L.A.

AU - Koops, M.

AU - Gout-Zwart, J.J.

AU - Beinema, M.J.

AU - Hemels, M.E.W.

AU - Postma, M.J.

AU - Brouwers, J.R.B.J.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - In 2012, the Dutch Health Council published a report addressing barriers for an early and broad introduction of direct oral anticoagulants (DOACs). The report raised concerns about the lack of an antidote, adherence, lack of monitoring in the case of overdose and the increased budget impact at DOAC introduction. In the past decade, international studies have shown that DOACs can provide healthcare benefits for a large number of patients. This has led to an increase in the prescription of DOACs, as they are an effective and user-friendly alternative to vitamin K antagonists (VKAs). Unlike VKAs, DOACs do not need monitoring of the international normalized ratio due to more predictable pharmacokinetics. However, the number of prescriptions of DOACs in the Netherlands is still lagging, compared to other European countries. This article highlights the potential health gains in the Netherlands if the use of DOACs were to increase, based on current international experience.

AB - In 2012, the Dutch Health Council published a report addressing barriers for an early and broad introduction of direct oral anticoagulants (DOACs). The report raised concerns about the lack of an antidote, adherence, lack of monitoring in the case of overdose and the increased budget impact at DOAC introduction. In the past decade, international studies have shown that DOACs can provide healthcare benefits for a large number of patients. This has led to an increase in the prescription of DOACs, as they are an effective and user-friendly alternative to vitamin K antagonists (VKAs). Unlike VKAs, DOACs do not need monitoring of the international normalized ratio due to more predictable pharmacokinetics. However, the number of prescriptions of DOACs in the Netherlands is still lagging, compared to other European countries. This article highlights the potential health gains in the Netherlands if the use of DOACs were to increase, based on current international experience.

KW - Coumarins

KW - DOAC

KW - Health benefits

KW - NOAC

KW - Patient preferences

KW - VKA

KW - adult

KW - budget

KW - controlled study

KW - drug overdose

KW - drug therapy

KW - human

KW - international normalized ratio

KW - monitoring

KW - Netherlands

KW - patient preference

KW - pharmacokinetics

KW - prescription

KW - review

KW - antidote

KW - antivitamin K

KW - coumarin derivative

M3 - Review article

VL - 76

SP - 426

EP - 430

JO - The Netherlands Journal of Medicine

JF - The Netherlands Journal of Medicine

SN - 0300-2977

IS - 10

ER -

ID: 72580715